Clinical Trials Logo

Unresectable Malignant Neoplasm clinical trials

View clinical trials related to Unresectable Malignant Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03240861 Terminated - Sarcoma Clinical Trials

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NYESO SCT
Start date: July 26, 2017
Phase: Phase 1
Study type: Interventional

This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body. The conditioning chemotherapy makes room in the patient?s bone marrow for new blood cells (PBMC) and blood-forming cells (stem cells) to grow. Giving NY-ESO-1 TCR PBMC and stem cells after the conditioning chemotherapy is intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer.

NCT ID: NCT02566421 Terminated - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

Start date: October 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies patients' genomic sequencing in determining specific treatments, also called Precision Medicine, in patients with cancer that has spread to other parts of the body (metastatic) and/or cannot be removed by surgery. Examining the genetic code of a patient's tumor, a mutation (a change in the deoxyribonucleic acid [DNA] sequence of a cell or gene) may be identified and matched with available treatment that targets the mutated gene or an alternative treatment that may provide benefit for the patient with the mutation identified. Precision medicine may impacts patient's response to treatment by targeting specific mutations and may increase survival and improve quality of life.

NCT ID: NCT01846429 Terminated - Pain Clinical Trials

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to: - Determine how well people tolerate sodium bicarbonate taken by mouth in higher doses than those usually given for heartburn. - Determine if sodium bicarbonate can reduce cancer-related pain.